(48) Accelerating Access: A Rapid Methadone Protocol for Outpatient Care

Background:
People who use non-prescribed opioids face a markedly elevated risk of overdose mortality, making timely and effective treatment with methadone potentially lifesaving. A 2021 meta-analysis demonstrated that methadone treatment is associated with a greater than 50% reduction in all-cause mortality compared with no treatment (RR 0.47; 95% CI 0.41–0.54)1. However, the illicit opioid supply today has shifted from heroin toward fentanyl and other high-potency synthetic opioids, resulting in higher opioid tolerance among patients initiating treatment. Clinically, this has translated into the need for higher methadone doses to achieve therapeutic suppression of withdrawal and craving.
Historically, methadone induction protocols have emphasized low starting doses and slow titration. While well-intentioned, these conservative approaches may contribute to a prolonged period of undertreatment during which patients continue to use non-prescribed opioids and remain at elevated risk of death. Notably, the first four weeks of methadone treatment have been associated with increased all-cause mortality (RR 2.81; 95% CI 1.55–5.09)1. In response to these evolving clinical realities, the 2024 SAMHSA guidelines introduced greater flexibility around initial dosing and titration, creating an opportunity to examine whether higher starting doses or rapid titration improve early treatment retention.


Methods:
We conducted a retrospective chart abstraction study using electronic health record data from an opioid treatment program (OTP) in Connecticut. Monthly cohorts of patients initiating methadone treatment from September to November from 2023 through 2025 were included. Prior to 2025, the standard methadone induction protocol had a starting dose of 30 mg with dose increases of 10 mg every three days. In 2025, the OTP adopted a revised rapid protocol with a 40 mg starting dose and 10 mg dose increases every two days. Of note, during 2024, there was a progressive adoption of the rapid protocol with clinician variability. No formal inclusion or exclusion criteria were applied.
Two reviewers independently abstracted data using a standardized coding framework, with manual extraction from intake physical examinations, methadone dosing orders, and point-of-care drug screens obtained at enrollment. Discrepancies were resolved through consensus adjudication. Primary exposure variables included the initial methadone dose and rate of dose escalation during early treatment. Primary outcomes were treatment retention and average dose at 7, 30, 60, and 90 days.
Multivariable logistic regression analyses were conducted in STATA to evaluate associations between dosing practices and retention, adjusting for relevant covariates.

Results:
A total of 273 patients were included across three protocol cohorts (2023 n=89, 2024 n=95, 2025 n=89). Early retention at 7 and 30 days was similar across years, ranging from 83–88% and 76–79%, respectively.
Differences emerged at later time points. Sixty-day retention increased to 75.3% in 2025 compared with 68.5% in 2023 and 64.2% in 2024. Ninety-day retention was highest in the 2025 cohort (70.8%), compared with 62.9% in 2023 and 64.2% in 2024, consistent with improved medium-term engagement following implementation of the rapid protocol
Mean methadone doses increased substantially following protocol revision. At day 7, average dose increased from 46.5 mg in 2023 to 70.8 mg in 2024 and 84.4 mg in 2025. Higher dosing persisted at later time points, with day-90 doses increasing from 74.0 mg in 2023 to 99.1 mg in 2025, reflecting faster titration and higher stabilization doses under the revised protocol. No adverse events were observed among patients treated under the 2025 rapid protocol.

Conclusion/discussion:
In this retrospective analysis, more rapid methadone dosing was associated with improved 90-day treatment retention. These findings are notable given that the protocol was implemented without formal inclusion or exclusion criteria, enhancing real-world applicability.
Rapid titration and higher initial dosing may better address withdrawal symptoms and cravings in the context of a fentanyl-dominant opioid supply, where baseline opioid tolerance is higher.
Importantly, no adverse events were observed among patients treated with the rapid protocol, supporting its safety in this setting. However, interpretation is limited by the observational design, modest sample size, and potential confounding, which preclude causal inference.
Overall, these findings suggest that rapid methadone induction may improve early treatment engagement without increasing adverse events and support the need for larger, multi-site studies to further inform dosing practices.

DEI:
Innovative induction protocols for medications for opioid use disorder have frequently focused on buprenorphine, while methadone practices have remained comparatively static. Buprenorphine prescribing emerged in deliberate contrast to the highly regulated methadone system and has undergone substantial evolution, including low-dose inductions, higher maximum dosing, long-acting injectable formulations, and major policy reforms such as elimination of the X-waiver.
In contrast, methadone treatment continues to exhibit wide variability across programs and regions, reflecting the absence of standardized, evidence-based dosing protocols. These disparities are reinforced by the historical segregation of addiction treatment in the United States: methadone programs are disproportionately concentrated in urban, predominantly minority communities, whereas office-based buprenorphine treatment is more common in higher-income caucasian neighborhoods. Expanding evidence-based flexibility in methadone dosing is therefore not only clinically imperative, but also a health equity intervention with the potential to reduce structural inequities in access to effective opioid treatment.


References:
1. Santo T, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry 2021;78(9):979-993
2. Jegede O, De Aquino JP, Hsaio C, et al. The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review. Journal of Addiction Medicine 2024;18(5):499-510. DOI: 10.1097/ADM.0000000000001356
3. Cohen SM, Straus E, Fiellin DA, et al. Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services. JAMA Netw Open.2025;8(8):e2526077. doi:10.1001/jamanetworkopen.2025.26077
4. Garg R, Luo J, Bozinoff N, et al. Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023. JAMA Netw Open. 2025;8(8):e2527290. doi:10.1001/jamanetworkopen.2025.27290
5. Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82-89. doi:10.1016/j.drugalcdep.2015.12.035